Cyclacel Pharmaceuticals, Inc.
CYCC
$7.99
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 10.00K | 4.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 10.00K | 4.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 0.00 | 10.00K | 4.00K |
| SG&A Expenses | 1.25M | 4.22M | 948.00K | 1.24M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.32M | 5.04M | 1.83M | 2.19M | 3.65M |
| Operating Income | -1.32M | -5.04M | -1.83M | -2.18M | -3.64M |
| Income Before Tax | -1.32M | -81.00K | -1.86M | -2.17M | -3.67M |
| Income Tax Expenses | 2.00K | -- | 1.19M | -210.00K | -412.00K |
| Earnings from Continuing Operations | -1.32M | -81.00K | -3.05M | -1.96M | -3.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.32M | -81.00K | -3.05M | -1.96M | -3.26M |
| EBIT | -1.32M | -5.04M | -1.83M | -2.18M | -3.64M |
| EBITDA | -1.32M | -5.03M | -1.83M | -2.18M | -3.64M |
| EPS Basic | -1.53 | -0.09 | -79.25 | -172.18 | -172.18 |
| Normalized Basic EPS | -0.94 | -3.64 | -30.15 | -- | -- |
| EPS Diluted | -1.53 | -0.09 | -79.25 | -172.18 | -172.18 |
| Normalized Diluted EPS | -0.94 | -3.64 | -30.15 | -- | -- |
| Average Basic Shares Outstanding | 875.90K | 863.90K | 38.50K | -- | -- |
| Average Diluted Shares Outstanding | 875.90K | 863.90K | 38.50K | 18.90K | 18.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -3.11% | -- | -- | -- | -- |